|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 35/04 | (2006.01) |
| A61K 38/1709 | (2013.01) | ||
| C12N 15/113 | (2010.01) | ||
| A61K 38/177 | (2013.01) | ||
| A61K 31/136 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/4155 | (2006.01) | ||
| A61K 31/18 | (2013.01) | ||
| A61K 31/416 | (2006.01) | ||
| A61K 31/265 | (2013.01) | ||
| A61K 31/415 | (2013.01) | ||
| A61K 31/4164 | (2013.01) | ||
| A61K 31/47 | (2013.01) | ||
| A61K 31/5377 | (2013.01) | ||
| G01N 33/5743 | (2013.01) | ||
| G01N2500/10 | (2013.01) | ||
| A61K 31/136 | (2013.01) | ||
| A61K 31/4155 | (2013.01) | ||
| A61K 31/416 | (2013.01) | ||
| C07F 9/6506 | (2013.01) | ||
| A61K 31/4174 | (2013.01) | ||
| A61K 31/675 | (2013.01) | ||
| C07D 233/64 | (2013.01) | ||
| A61K 31/195 | (2013.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) |
| (11) | Number of the document | 3626309 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19189895.6 |
| Date of filing the European patent application | 2013-08-13 | |
| (97) | Date of publication of the European application | 2020-03-25 |
| (45) | Date of publication and mention of the grant of the patent | 2023-03-08 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201261682339 P | 2012-08-13 | US | |
| 201361784057 P | 2013-03-14 | US |
| (72) |
TAVAZOIE, Sohail , US
PENCHEVA, Nora, G. , US
|
| (73) |
The Rockefeller University ,
1230 York Avenue, New York, NY 10065,
US
|
| (54) | LXRBETA AGONIST FOR THE TREATMENT OF CANCER |
| LXRBETA AGONIST FOR THE TREATMENT OF CANCER |